Theseus Pharmaceuticals I... (THRX)
NASDAQ: THRX
· Real-Time Price · USD
4.07
0.01 (0.25%)
At close: Feb 13, 2024, 9:59 PM
Theseus Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 488.37K | 614.82K | 456.11K | 300.96K | 148.96K | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -488.37K | -614.82K | -456.11K | -300.96K | -148.96K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -66.52M | -66.07M | -60.56M | -54.09M | -47.27M | -38.69M | -33.43M | -27.34M | -21.57M | -15.62M | -8.81M |
Interest Income | 7.44M | 4.54M | 1.76M | 1.76M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -56.61M | -57.85M | -54.7M | -50.61M | -45.55M | -38.17M | -33.33M | -27.31M | -21.54M | -15.6M | -8.79M |
Net Income | -55.86M | -55.9M | -52.31M | -50.61M | -43.83M | -37.66M | -33.25M | -27.31M | -21.54M | -15.6M | -8.79M |
Selling & General & Admin | 19.3M | 18.94M | 19.01M | 18.39M | 16.93M | 14.78M | 12.38M | 9.01M | 5.77M | 3.55M | 1.22M |
Research & Development | 47.22M | 47.13M | 41.55M | 35.7M | 30.34M | 23.91M | 21.05M | 18.33M | 15.79M | 12.07M | 7.59M |
Other Expenses | n/a | n/a | n/a | 82K | 85K | 87K | 94K | 28K | 23K | 21K | 14K |
Operating Expenses | 66.52M | 66.07M | 60.56M | 54.09M | 47.27M | 38.69M | 33.43M | 27.34M | 21.57M | 15.62M | 8.81M |
Interest Expense | 1.72M | 1.72M | 1.72M | 1.72M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 66.52M | 66.07M | 60.56M | 54.09M | 47.27M | 38.69M | 33.43M | 27.34M | 21.57M | 15.62M | 8.81M |
Income Tax Expense | -775K | -1.96M | -2.39M | n/a | -1.72M | -518K | -94K | -28K | -23K | -21K | -14K |
Shares Outstanding (Basic) | 43.8M | 43.74M | 42.37M | 38.7M | 38.59M | 38.42M | 38.25M | 35.88M | 35.86M | 35.86M | 25.37M |
Shares Outstanding (Diluted) | 43.8M | 43.74M | 42.37M | 38.7M | 38.59M | 38.42M | 38.25M | 35.88M | 35.86M | 35.86M | 25.37M |
EPS (Basic) | -1.34 | -1.38 | -1.33 | -1.31 | -1.15 | -1.01 | -0.91 | -0.82 | -0.69 | -0.54 | -0.35 |
EPS (Diluted) | -1.34 | -1.38 | -1.33 | -1.31 | -1.15 | -1.01 | -0.91 | -0.82 | -0.69 | -0.54 | -0.35 |
EBITDA | -64.77M | -64.3M | -58.8M | -52.32M | -47.23M | -38.68M | -33.42M | -27.33M | -21.56M | -15.62M | -8.8M |
EBIT | -63.05M | -62.59M | -57.08M | -50.61M | -47.27M | -38.69M | -33.43M | -27.34M | -18.68M | -12.73M | -5.92M |
Depreciation & Amortization | 83K | 79K | 69K | 50K | 31K | 15K | 59.81K | 59.81K | 113.94K | 112.94K | 57.13K |